What do the expense ratios of IBB and XBI mean for long-term costs?

IBB charges an expense ratio of 0.44%, while XBI charges 0.35%. This creates a 0.09 percentage point annual cost difference. Over extended periods, higher fees can reduce net returns, assuming equal gross performance. The impact grows with time and asset size. XBI's lower fee structure may be more cost-efficient for long-term holders. These figures come directly from fund data and do not include trading commissions or other non-recurring costs. Always consider total investment expenses.

How do IBB and XBI differ in tracking their biotechnology market exposure?

IBB focuses on established biotechnology leaders through a diversified large-cap approach, with top holdings like GILD at 8.37% and VRTX at 7.61%. XBI uses an equal-weighted structure, spreading exposure across more constituents with individual positions below 2%, such as TWST and MRNA. This creates different risk profiles. IBB emphasises mature companies, while XBI provides broader representation of smaller biotech firms. Both track biotechnology, but their methodologies significantly shape the actual investment exposure.

What does the shorter operational history of XBI imply compared to IBB?

XBI launched in January 2006, giving it a shorter track record than IBB, which began in February 2001. A longer operational history allows for more extensive performance data across various market cycles. However, both funds have over fifteen years of history, providing substantial evidence. IBB's additional years may offer slightly more data points for analysis, but XBI's structure has been in place long enough to evaluate its equal-weighted approach effectively in multiple market environments.

What are the shared top holdings between IBB and XBI?

GILD, MRNA, and NTRA appear in the top ten holdings of both IBB and XBI. In IBB, GILD represents 8.37% of the fund, while MRNA and NTRA are smaller positions. In XBI, these three constituents each hold less than 2%. The presence of identical holdings demonstrates some market overlap, yet the weighting differences highlight distinct portfolio construction methods. IBB concentrates more in large-cap leaders, whereas XBI maintains a flatter allocation across its top holdings.

How do the dividend yields of IBB and XBI compare?

IBB offers a dividend yield of 0.16%, while XBI provides 0.36%. This 0.20 percentage point difference reflects varying distribution policies among biotechnology companies. Neither yield is particularly high, consistent with the sector's focus on growth and research rather than income generation. XBI's marginally higher yield may appeal to investors prioritising modest distributions, but biotechnology investments generally emphasise capital appreciation over regular income from dividends.

Which investing goals do IBB and XBI typically align with?

IBB suits investors seeking exposure to established biotechnology leaders like GILD and VRTX, offering a large-cap focused structure with concentrated top holdings. XBI appeals to those wanting broader representation across the biotechnology sector through equal weighting, including smaller positions in companies such as TWST and MRNA. IBB emphasises quality and maturity, while XBI provides diversified exposure to the entire biotechnology landscape. Neither fund addresses all investment objectives equally.

How do the net assets of IBB and XBI compare in practice?

IBB manages $10.4 billion in net assets, marginally exceeding XBI's $10.3 billion. This slight difference has minimal practical impact on most investors, as both funds are sufficiently large and widely held. Higher assets under management can enhance liquidity and reduce trading impact, but at these levels, both ETFs offer substantial accessibility. The near-identical asset sizes indicate comparable adoption by institutional and retail investors seeking biotechnology sector exposure.

Why do both funds show 'not available' for index tracking information?

Both IBB and XBI list 'not available' for their tracked indices. This limitation affects transparency when evaluating benchmark methodologies. Investors cannot directly compare the underlying index rules for these funds using this data point. Without index details, assessing tracking differences becomes reliant on portfolio holdings and weighting structures. This data gap may require consulting additional fund documentation to fully understand each index's composition and rebalancing approach.

What does the absence of sector weights indicate about these funds?

Both IBB and XBI report 'not available' for sector weights in the provided data. This means precise industry breakdowns within the biotechnology category cannot be verified. Investors should not assume identical sector allocations. The lack of sector weighting data emphasises the importance of examining individual holdings to understand true exposure. This limitation affects the ability to assess diversification nuances within the biotechnology landscape between the two funds.

Can these comparison figures determine which ETF is better?

No, these figures alone cannot determine superiority. IBB's concentration in established leaders contrasts with XBI's equal-weighted breadth. Fee differences exist, but their impact varies by investment horizon and portfolio size. Dividend yields are modest in both cases. Investors must assess personal risk tolerance, investment duration, and whether they prefer large-cap stability or diversified sector exposure. Educational disclaimers note this is comparative analysis, not investment advice. Your specific financial situation dictates the most suitable approach.

What important educational disclaimer applies to this comparison?

This information is strictly educational and does not constitute financial advice. The comparison highlights structural differences between IBB and XBI without evaluating their suitability for individual circumstances. Data comes from third-party sources and may not reflect real-time conditions. Investors should independently research fund objectives, consult qualified financial professionals, and consider their personal risk tolerance before making investment decisions. Past performance of either fund does not guarantee future results.

IBB vs XBI

Two funds, one decision: we compare cost, performance and what each ETF actually holds in October 2026.

Compare IBB (iShares Biotechnology ETF) and XBI (SPDR S&P Biotech ETF). This page examines fees, holdings, dividends, and how each fund tracks its market to help you understand their structures. Educational content, not financial advice.

Fund Snapshot

Key Fund Metrics

IBB

Metric

XBI

0.44%

Expense Ratio

0.35%

0.16%

Dividend Yield

0.36%

$10.45B

Net Assets

$10.34B

249

Holdings

167

Feb 5, 2001

Inception Date

Jan 31, 2006

–

Index Tracked

–

Health

Fund Category

Health

XBI costs about $9.00 less per year for every $10,000 invested.

Shared Top Holdings

Holding	IBB	XBI
GILDGilead Sciences, Inc.	8.37%	1.48%
MRNAModerna, Inc.	4.06%	1.63%
NTRANatera, Inc.	3.59%	1.61%

Discover More Comparisons

IBB vs IBBQ

Compare IBB and IBBQ ETFs on expense ratios, net assets, dividend yields, and top holdings. Index tracking details not available for either fund.

IBB vs XLV

Compare IBB and XLV ETFs on expense ratios, holdings, dividends, and tracking. IBB: 0.44% fees, 0.16% yield. XLV: 0.08% fees, 1.51% yield. Neutral analysis.

IBBQ vs XBI

Compare IBBQ vs XBI ETF. Explore key differences in expense ratios, net assets, dividend yields, holdings and index focus. Facts for your research.

Investment Analysis

IBB

Pros

IBB offers substantial scale with net assets of $10.4 billion and a long operational history since February 2001.
The fund provides exposure to established biotechnology leaders including GILD at 8.37% and VRTX at 7.61%.
Investors benefit from a diversified large-cap focus, with the top ten holdings featuring major names like AMGN and REGN.

Considerations

The expense ratio of 0.44% is higher than the 0.35% charged by the comparable XBI fund.
A low dividend yield of 0.16% may not suit investors seeking regular income from their holdings.
The index tracked is not available, which might limit transparency for investors who rely on benchmark methodology.

XBI

Pros

XBI charges a lower expense ratio of 0.35% compared to IBB, potentially reducing costs over time.
The fund provides broader exposure through equal-weighted holdings, with top positions like TWST and MRNA each below 2%.
It offers a slightly higher dividend yield of 0.36% than IBB, though yields remain generally modest.

Considerations

Net assets of $10.3 billion are marginally lower than IBB, though both funds remain widely held.
Since inception in January 2006, the fund has a shorter operational history than IBB’s 2001 start.
The index tracked is not available, restricting ability to verify the specific benchmark against which the fund is measured.

About IBB and XBI

IBB (IBB)

The iShares Biotechnology ETF (IBB) offers investors diversified access to the dynamic biotechnology sector. As an exchange-traded fund, it tracks the performance of companies involved in medical research, drug development, and biotech innovation. With 249 holdings and net assets of USD 10.45 billion, IBB provides broad exposure to this capital-intensive industry. It carries an expense ratio of 0.44% and a modest dividend yield of 0.16%, reflecting the sector's focus on reinvestment for growth rather than income. Investors should note that biotechnology stocks can be highly volatile, driven by regulatory approvals and clinical trial outcomes. This ETF suits those seeking general exposure to healthcare innovation who understand that values can rise and fall significantly.

XBI (XBI)

The SPDR S&P Biotech ETF offers investors access to a broad selection of U.S. biotechnology companies, currently holding approximately 167 stocks. As a Health sector fund, it tracks the performance of the S&P Biotechnology Select Industry Index, which uses equal weighting to give smaller companies a greater influence compared to market-cap weighted indices. With net assets of USD 10.34 billion and an expense ratio of 0.35%, it is a substantial vehicle for sector exposure. The fund currently provides a dividend yield of 0.36%. Biotech is known for its volatility and innovation potential, meaning values can rise and fall significantly. This fund is designed for general educational purposes and does not guarantee returns, so investors should consider their risk tolerance before investing.

Buy IBB or XBI in Nemo

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

IBB vs XBI

Fund Snapshot